DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alzheimer’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Alzheimer’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alzheimer’s Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alzheimer’s Disease: An Overview
Alzheimer’s disease is a debilitating neurological disorder that gradually erodes memory and cognitive abilities, as well as the ability to perform even the most basic tasks. Alzheimer’s patients have difficulty doing simple tasks such as driving a car, preparing a meal, or paying bills. They can repeatedly ask the same questions, become easily disoriented, accidentally drop or misplace objects, and find even simple things perplexing. Some people become worried, frustrated, or aggressive as the disease progresses.
Alzheimer’s disease is a disease whose precise causes are unknown. However, at a fundamental stage, brain proteins malfunction, disrupting the work of brain cells (neurons) and triggering a cascade of toxic events. Neurons become weakened, lose their ties, and ultimately die. The most well-known risk factor for Alzheimer’s disease is age. Alzheimer’s disease is not a natural part of aging, but it does increase the chances of developing it as the person gets older. It is accompanied by a family history of the said disease, or it is also observed that many people with Down’s syndrome experience Alzheimer’s later in their life.
The current treatment regime is mostly symptomatic to slow disease progression and improve quality of life. Pharmacological therapies for symptomatic treatment, such as acetylcholinesterase inhibitors (AChEIs), and NMDA receptor antagonist, memantine, have been available for over a decade. Recently, more targeted, monoclonal antibodies that target amyloid beta-proteins, Biogen and Eisai’s ADUHELM (aducanumab), and LEQEMBI (lecanemab) have received US FDA approval. But both have serious adverse events like edema and hemorrhage.
Several drugs are being investigated to cater to the unmet needs of patients. Several novel therapies by Anavex Life Sciences, Alzheon, Athira Pharma, Annovis Bio, Eli Lilly, BioVie, AB Science, Novo Nordisk, Cassava Sciences, TauRx Therapeutics, KeifeRx, AriBio, Cerecin, Eisai, and others are in late stages of development with the potential to change the regime. The early-stage pipeline is also robust, with multiple drugs being evaluated.
Alzheimer’s Disease Market Key Facts
-
Among the 7MM, the US had the largest market share in Alzheimer’s disease, with a revenue of USD 1,751.7 million in 2022. The market size of Alzheimer’s disease in the US will increase at a significant CAGR due to increasing awareness of the disease and the launch of the emerging therapy.
-
The total market size of Alzheimer’s disease in EU4 and the UK was calculated to be USD 794.4 million in 2022, which was approximately 23.0% of the total market revenue for the 7MM. Among EU4 and the UK countries, Germany accounted for the maximum market size of Alzheimer’s disease in 2022, while the UK occupied the bottom of the ladder.
-
Japan accounted for the second-largest market of Alzheimer’s disease among the 7MM, with a revenue of approximately USD 914.5 million in 2022, expected to increase during the forecast period.
-
DelveInsight estimates that ADUHELM accounted for USD 4.6 million in the US in 2022. This revenue is projected to increase with hopes for traditional approval.
-
In 2022, the total diagnosed prevalent cases of Alzheimer’s disease were estimated to be approximately 15,083,370 cases in the 7MM.
-
In the US, there were approximately 6,186,284 diagnosed prevalent cases of Alzheimer’s disease in 2022. These were nearly 41% of the total cases in the 7MM.
-
In 2022, among the 7MM, Japan accounted for the second-highest diagnosed prevalent cases of Alzheimer’s disease, contributing nearly 26%, while the UK accounted for the least with nearly 4% of the total diagnosed prevalent cases.
-
In 2022, EU4 and the UK accounted for nearly 33% of the total diagnosed prevalent cases of Alzheimer’s in the 7MM. There were approximately 4,942,376 total diagnosed prevalent cases of Alzheimer’s disease.
-
Among EU4 and the UK, Germany accounted for the highest (nearly 31%) total diagnosed prevalent cases of Alzheimer’s disease, with approximately 1,510,515 cases, followed by France (nearly 24%).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alzheimer’s Disease pipeline therapies. It also thoroughly assesses the Alzheimer’s Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Alzheimer’s Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Alzheimer’s Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Alzheimer’s Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Alzheimer’s Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Alzheimer’s Disease Epidemiology, Segmented as –
-
Total prevalent cases of Alzheimer’s Disease (AD) in the 7MM [2019-2032]
-
Total diagnosed prevalent cases of Alzheimer’s disease in the 7MM [2019-2032]
-
Total age-specific diagnosed prevalent cases of Alzheimer’s Disease in the 7MM [2019-2032]
-
Total severity-specific diagnosed prevalent cases of Alzheimer’s Disease in the 7MM [2019-2032]
-
Total treated cases of Alzheimer’s Disease in the 7MM [2019-2032]
-
Total gender-specific diagnosed prevalent cases of Alzheimer’s Disease in the 7MM [2019-2032]
Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Alzheimer’s Disease market or expected to be launched during the study period. The analysis covers the Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Alzheimer’s Disease drugs based on their sale and market share.
The report also covers the Alzheimer’s Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Alzheimer’s Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Alzheimer’s Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
Alzheimer’s Disease Therapeutics Analysis
Alzheimer’s disease is a complex neurological issue. Most medications are most effective in patients who are in the early to mid stages of Alzheimer’s disease. The prescribed therapies may temporarily slow down certain symptoms, such as memory loss, however, it is important to note that none of these drugs can cure the condition. The U.S. Food and Drug Administration (FDA) has approved pharmacotherapy treatment to relieve the cognitive symptoms (memory loss, uncertainty, and difficulty with rational reasoning) in Alzheimer’s patients.
Several major pharma and biotech companies are developing therapies for Alzheimer’s disease. Currently, Eli Lilly and Company is leading the therapeutics market with its Alzheimer’s disease drug candidates in the most advanced stage of clinical development.
Various therapies like Anavex Life Sciences’s ANAVEX2-73 (blarcamesine), Alzheon’s ALZ-801 (valiltramiprosate), Athira Pharma’s fosgonimeton (ATH-1017), Annovis Bio’s buntanetap, Eli Lilly’s donanemab (LY3002813), BioVie’s NE3107, Cassava Sciences’ simufilam (PTI-125), and TauRx Therapeutics’ hydromethylthionine mesylate (TRx0237) among others are anticipated to enter the market during the forecast period.
Alzheimer’s Disease Companies Actively Working in the Therapeutics Market Include
-
BioVie
-
AB Science
-
Cassava Sciences
-
Eli Lilly
-
TauRx Therapeutics
-
Novo Nordisk
-
KeifeRx
-
Eli Lilly
-
AriBio
-
Cerecin
-
Alzheon
-
Neurim Pharmaceuticals/Syneos Health
-
Athira Pharma
-
Annovis Bio
-
Anavex Life Sciences
-
AgeneBio
-
Eisai
And Many Others
Emerging and Marketed Alzheimer’s Disease Therapies Covered in the Report Include:
-
ADUHELM (aducanumab): Biogen and Eisai
-
LEQEMBI (lecanemab): Biogen and Eisai
-
NE3107: BioVie
-
Donanemab (LY3002813): Eli Lilly
-
Simufilam (PTI-125): Cassava Sciences
-
Hydromethylthionine mesylate/TRx0237: TauRx Therapeutics
-
ALZ-801 (valiltramiprosate): Alzheon
-
Fosgonimeton (ATH-1017): Athira Pharma
-
Buntanetap: Annovis Bio
-
ANAVEX2-73 (blarcamesine): Anavex Life Sciences
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alzheimer’s Disease Competitive Intelligence Analysis
4. Alzheimer’s Disease Market Overview at a Glance
5. Alzheimer’s Disease Disease Background and Overview
6. Alzheimer’s Disease Patient Journey
7. Alzheimer’s Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Alzheimer’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer’s Disease Unmet Needs
10. Key Endpoints of Alzheimer’s Disease Treatment
11. Alzheimer’s Disease Marketed Therapies
12. Alzheimer’s Disease Emerging Drugs and Latest Therapeutic Advances
13. Alzheimer’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Alzheimer’s Disease Market Outlook (In US, EU5, and Japan)
16. Alzheimer’s Disease Companies Active in the Market
17. Alzheimer’s Disease Access and Reimbursement Overview
18. KOL Views on the Alzheimer’s Disease Market
19. Alzheimer’s Disease Market Drivers
20. Alzheimer’s Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Desmoplastic Small Round Cell Tumors (DSRCT) Market
“Desmoplastic Small Round Cell Tumors (dsrcts) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Desmoplastic Small Round Cell Tumors market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the DSRCT market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research